hotspot -WSS

hotspot

author：hotspot 2025-09-27 09:40:29 - browse：16787

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Vertex non

entertainment

WSS

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Akili, maker of video game for ADHD, to be acquired for 34 million

Childbirth

Health insurers say they are turning to AI to cut costs, improve care

Biogen walks away from Aduhelm, years after polarizing approval

Zyn nicotine pouches become unlikely player in latest culture war

knowledge

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Affirmative action in medical school literally saved lives

Wegovy leads to weight loss. Can it treat depression, too?

Tori Bowie and the unacceptable rates of Black maternal death

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Walensky prepares to leave CDC — and Congress — behind

Report: NIH

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare Advantage insurers face 0.2% cut to 2025 payments

Psychedelics group wrestles with new pharma identity

Syphilis numbers in the United States reach record heights

Wikipedia

Reconstructing family trees of blood cells may help predict disease

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Scientists successfully use ultrasound imaging to map brain activity

First Opinion Podcast: What happens when kids become caregivers?

Merck, Johnson & Johnson CEOs will testify on high drug prices

Pancreatic cancer early detection could be helped by AI

focus

hotspot

entertainment

knowledge